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ronedarone Is Superior to Placebo
he Case for Optimism
read with interest the study by Piccini et al. (1) that evaluated
ronedarone for treating atrial fibrillation (AF). I agree with the
rimary conclusion that amiodarone is more effective than drone-
arone for maintenance of sinus rhythm, as would be expected on
he basis of the DIONYSOS (Efficacy and Safety of Dronedarone
ersus Amiodarone for the Maintenance of Sinus Rhythm in
atients with Atrial Fibrillation) trial (2). However, I have concern
bout the dronedarone data that might have mistakenly led to an
verly negative appraisal of its effect.
In Figure 2A of the paper (1), the authors present an odds ratio
lot for EURIDIS (EURopean trial In atrial fibrillation or flutter
atients receiving Dronedarone for the maIntenance of Sinus
hythm) and ADONIS (American-Australasian trial with Drone-
arONe In atrial fibrillation or flutter patients for the maintenance
f Sinus rhythm) (3). The data as presented suggest that placebo
ad efficacy comparable to dronedarone in these studies, which
irectly contradicts the studies’ conclusions. The answer to this
nconsistency lies in the supporting data to the right of the odds
atio plot. For EURIDIS, the denominators of 411 and 201
atients/treatment arm come from the second line of Table 2 of
he trial’s publication (3). The numerators are supposed to repre-
ent the number of patients with recurrent AF and are also taken
rom Table 2, 5th line of data (1).
These numbers do not make sense as representing the number
f patients with recurrent AF at 1 year. They would correspond to
4.7% (307 of 411) and 73.6% (148 of 201) with recurrent AF at
year for dronedarone and placebo, respectively, and thus would
how no difference between the 2 treatments. The actual reported
ecurrence rates of AF at 1 year (Table 2, line 3 [1]) are 67.1% and
7.5% for dronedarone and placebo, respectively. Instead, I believe
hat the number of patients presented in line 5 of the table likely
epresents the denominator for the analysis that follows, much like
he number of patients in line 2 also is a denominator, and absolute
umbers of patients with recurrent AF are not specified, favoring
resenting these data as percentages (1). It is also possible that the eumbers in line 5 present some other subselection of the total
atient population, but it is inconsistent with the results of
URIDIS to assume that they represent the number of patients
ith recurrent AF. The same number sources are used for
DONIS. This artificially makes dronedarone seem the same as
lacebo in terms of AF recurrence rate at 1 year, a finding that
ignificantly differs from the data in Table 2 and the Kaplan-Meier
lots in Figure 2 (3).
While awaiting clarification from the authors of EURIDIS and
DONIS, there seems to be an error here that creates an overly
egative conclusion as to the effect of dronedarone. After all,
ronedarone has already been demonstrated in several studies to be
uperior to placebo (3,4) and not equal to it, as is suggested by the
rticle by Piccini et al. (1).
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eply
e appreciate the opinions of Dr. Lewalter regarding our meth-
dology (1), particularly the use of intention-to-treat populations.
he meta-analysis was constructed with conservative assumptions
o reduce the risk of type I error. From this perspective, when
stimating potential differences among treatments, biases that
ake the treatments seem more similar (including crossovers or
ailure to receive treatment) are conservative assumptions.
ntention-to-treat provides the best pragmatic estimate of a given
herapeutic strategy (in this case, therapy with dronedarone vs.
miodarone) (2). Often disagreement arises over the exact defini-
ion of intention-to-treat in an individual trial. In our meta-
nalysis we attempted to include patients in the denominator
ccording to treatment allocation at the time of randomization.
Although the primary end point in EURIDIS (EURopean trial In
trial fibrillation or flutter patients receiving Dronedarone for the
aIntenance of Sinus rhythm) and ADONIS (American-
ustralasian trial with DronedarONe In atrial fibrillation or flutter
atients for the maintenance of Sinus rhythm) (3) was the time to
ecurrence of atrial fibrillation (AF), in our analysis the primary
fficacy end point was recurrent AF at follow-up. This approach was
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March 9, 2010:1051–4hosen for 2 reasons. First, recurrence of AF at 1 year is a common
nd clinically relevant end point. Second, recurrent AF data (as
pposed to time-to-recurrence) were available for all trials in our
eta-analysis except the ATHENA (A Trial With Dronedarone to
revent Hospitalization or Death in Patients With Atrial Fibrilla-
ion), which did not report rhythm status (4).
The numerators and denominators for the maintenance of sinus
hythm analysis reflect an intention-to-treat approach based upon
reatment allocation at randomization—acknowledging differences in
xperimental design across the incorporated trials. Patients in
AFNE (Dronedarone Atrial FibrillatioN study after Electrical
ardioversion) (5) were reported according to assignment at random-
zation. Cardioversion was performed at 5 to 7 days in a subgroup, and
he on-treatment analysis conducted in DAFNE only included these
atients, as noted by Dr. Lewalter. Alternatively, GEFACA (Grupo
e Estudio de Fibrilacio´n Auricular Con Amiodarona) (6) had a
uch longer 4-week run-in period in which patients who remained in
F had to agree to cardioversion, and therefore we used a denomi-
ator at the end of the run-in period. With respect to SAFE-T
Sotalol Amiodarone Atrial Fibrillation Efficacy Trial) (7), 14 patients
3%) were withdrawn from the study; however, their inclusion does
ot meaningfully change the odds ratio (OR) for the treatment effect.
Both Drs. Lewalter and Cooper question the numerators used
or the maintenance of sinus rhythm from EURIDIS and
DONIS. We included those with recurrent AF on the basis of
able 2, row 5 “Recurrence at 12 mo, No. of patients.” These
umbers for the 1-year recurrence rate in EURIDIS (74.7%) are
onsistent with the effect reported in the DIONYSOS (Efficacy
nd Safety of Dronedarone versus Amiodarone for the Mainte-
ance of Sinus Rhythm in Patients with Atrial Fibrillation) trial
73.9%) (8). We agree with Dr. Cooper that greater clarity in the
ublished EURIDIS and ADONIS results would be desirable.
If one assumes the numerators and denominators for AF
ecurrence are as suggested by Dr. Cooper (EURIDIS: Placebo
56 of 201, Dronedarone 276 of 411; ADONIS: Placebo 151 of
08, Dronedarone 255 of 417), the overall conclusions are similar.
ssuming these results, dronedarone for the prevention of recur-
ent AF has an OR of 0.54 (95% confidence interval [CI]: 0.42 to
.71) compared with placebo. When incorporated into an indirect
eta-analysis, the estimated effect of amiodarone versus droneda-
one does not meaningfully change (OR: 0.23, 95% CI: 0.14 to
.38). Estimates using the totality of the evidence, including the
esults from the DIONYSOS trial, still indicate superiority of
miodarone over dronedarone (OR: 0.33, 95% CI: 0.14 to 0.52).
verall estimates using risk differences suggest that use of amio-
arone would be associated with 270 fewer AF recurrences/1,000
atients treated compared with dronedarone (95% CI: 0.35 to
0.19). The CI of this result has the same lower boundary as our
nitial analysis (OR: 0.36, 95% CI: 0.52 to 0.19).
We realize that the type and duration of AF are both predictive of
F recurrence (9,10). DAFNE, EURIDIS, and ADONIS excluded
atients with long-standing persistent AF. By contrast, SAFE-T
xcluded patients with paroxysmal AF, and GEFACA exclusively en-
olled patients with long-standing persistent/chronic AF. Although it
ould be desirable to adjust for these differences as a meta-regression
nalysis, this would require more detailed data than provided in the
ublished tables.
Recognizing the limitations inherent with indirect comparisons, we
urposefully incorporated the indirect estimates with head-to-head data
omparing dronedarone and amiodarone in the DIONYSOS trial.
he data from this clinical trial were consistent with our indirect preatment estimates. Our report conservatively summarizes the best
vailable evidence for the safety and efficacy of both of these important
reatment options. We wholeheartedly agree with Professor Lewalter
hat large pragmatic trials focused on definitive outcomes are crucial
or refining our understanding of these drugs.
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ardiac Rehabilitation for
atients With Ventricular
ssist Devices
n Offer to Improve
trong Collaborative Relationships
he review by Wilson et al. (1) outlines several important
rinciples in the outpatient management of patients with ventric-
